In a media release, BioElectronics Corporation, headquartered in Frederick, Md, announces its endorsement of the US Food and Drug Administration’s final rule 890.5290 on nonthermal pulsed shortwave devices.
This endorsement was published recently in the Federal Register.
“I am pleased the agency has completed this step in streamlining the regulatory requirements for making available to Americans, the same safe drug-free pain relief option enjoyed in other countries around the world,” says Andrew J. Whelan, BioElectronics Corp resident, in the release.
BioElectronics Corp produces noninvasive electroceuticals and disposable, drug-free therapy devices, per the release.
For more information, visit BioElectronics Corporation.
[Source: BioElectronics Corp]
